Agoracom: Small Cap Investment - Zenith Epigenetics - BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

posted on May 20, 2019 05:09PM

A new paper on BRD4 and castrate-resistant prostrate cancer just came out. "BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK." I don't have access to the full text, but here is a link to the abstract:

http://mcr.aacrjournals.org/content/early/2019/05/17/1541-7786.MCR-18-1279.full-text.pdf

7 Recommendations

Re: BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK